Sun Hwa Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3389670/publications.pdf

Version: 2024-02-01

36 papers	1,584 citations	361413 20 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	2616 citing authors

#	Article	IF	Citations
1	Exosomeâ€Guided Phenotypic Switch of M1 to M2 Macrophages for Cutaneous Wound Healing. Advanced Science, 2019, 6, 1900513.	11.2	276
2	Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA. Scientific Reports, 2014, 4, 6878.	3.3	118
3	Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. Journal of Controlled Release, 2015, 198, 1-9.	9.9	117
4	Chemical and structural modifications of RNAi therapeutics. Advanced Drug Delivery Reviews, 2016, 104, 16-28.	13.7	110
5	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimineâ€“Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. ACS Nano, 2017, 11, 10135-10146.	14.6	84
6	Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo. Journal of Controlled Release, 2015, 220, 631-641.	9.9	76
7	MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. Biomaterials, 2014, 35, 1744-1754.	11.4	73
8	Development of Biocompatible HA Hydrogels Embedded with a New Synthetic Peptide Promoting Cellular Migration for Advanced Wound Care Management. Advanced Science, 2018, 5, 1800852.	11.2	69
9	Structural modification of siRNA for efficient gene silencing. Biotechnology Advances, 2013, 31, 491-503.	11.7	58
10	Sustained Exosomeâ€Guided Macrophage Polarization Using Hydrolytically Degradable PEG Hydrogels for Cutaneous Wound Healing: Identification of Key Proteins and MiRNAs, and Sustained Release Formulation. Small, 2022, 18, e2200060.	10.0	54
11	Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy. Cancers, 2021, 13, 4435.	3.7	52
12	Rolling circle transcription-based polymeric siRNA nanoparticles for tumor-targeted delivery. Journal of Controlled Release, 2017, 263, 29-38.	9.9	49
13	Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemiaâ€“reperfusion injury: Use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier. Journal of Controlled Release, 2013, 168, 125-134.	9.9	45
14	Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. International Journal of Pharmaceutics, 2012, 434, 488-493.	5.2	43
15	Cardiac RNAi therapy using RAGE siRNA/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction. Biomaterials, 2014, 35, 7562-7573.	11.4	38
16	Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. Journal of Controlled Release, 2017, 267, 203-213.	9.9	35
17	Development of microRNA-21 mimic nanocarriers for the treatment of cutaneous wounds. Theranostics, 2020, 10, 3240-3253.	10.0	32
18	Self-assembled PEGylated albumin nanoparticles (SPAN) as a platform for cancer chemotherapy and imaging. Drug Delivery, 2018, 25, 1570-1578.	5.7	28

#	Article	IF	Citations
19	Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles. Biochemical and Biophysical Research Communications, 2017, 489, 35-41.	2.1	25
20	The potential and advances in RNAi therapy: Chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. Journal of Controlled Release, 2014, 193, 113-121.	9.9	21
21	Simultaneous regulation of apoptotic gene silencing and angiogenic gene expression for myocardial infarction therapy: Single-carrier delivery of SHP-1 siRNA and VEGF-expressing pDNA. Journal of Controlled Release, 2016, 243, 182-194.	9.9	21
22	RAGE siRNA-mediated gene silencing provides cardioprotection against ventricular arrhythmias in acute ischemia and reperfusion. Journal of Controlled Release, 2015, 217, 315-326.	9.9	20
23	Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction. Archives of Pharmacal Research, 2015, 38, 1317-1324.	6.3	16
24	Versatile activatable vSIRPÎ±-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells. Journal of Controlled Release, 2020, 323, 376-386.	9.9	16
25	Ultraefficient extracellular vesicleâ€“guided direct reprogramming of fibroblasts into functional cardiomyocytes. Science Advances, 2022, 8, eabj6621.	10.3	16
26	Extracellular vesicle-guided in situ reprogramming of synovial macrophages for the treatment of rheumatoid arthritis. Biomaterials, 2022, 286, 121578.	11.4	16
27	A Trojan-Horse Strategy by In Situ Piggybacking onto Endogenous Albumin for Tumor-Specific Neutralization of Oncogenic MicroRNA. ACS Nano, 2021, 15, 11369-11384.	14.6	15
28	Crossâ€linked Iron Oxide Nanoparticles for Therapeutic Engineering and in Vivo Monitoring of Mesenchymal Stem Cells in Cerebral Ischemia Model. Macromolecular Bioscience, 2014, 14, 380-389.	4.1	11
29	Implication of multivalent aptamers in DNA and DNAâ€“RNA hybrid structures for efficient drug delivery in vitro and in vivo. Journal of Industrial and Engineering Chemistry, 2018, 60, 250-258.	5.8	9
30	Enhanced Cytoplasmic Delivery of RAGE siRNA Using Bioreducible Polyethylenimineâ€based Nanocarriers for Myocardial Gene Therapy. Macromolecular Bioscience, 2015, 15, 1755-1763.	4.1	8
31	MicroRNA-mediated non-viral direct conversion of embryonic fibroblasts to cardiomyocytes: comparison of commercial and synthetic non-viral vectors. Journal of Biomaterials Science, Polymer Edition, 2017, 28, 1070-1085.	3.5	8
32	Extracellular Vesicles as Potential Theranostic Platforms for Skin Diseases and Aging. Pharmaceutics, 2021, 13, 760.	4.5	8
33	Nanoscale polyelectrolyte complexes encapsulating mRNA and long-chained siRNA for combinatorial cancer gene therapy. Journal of Industrial and Engineering Chemistry, 2018, 64, 430-437.	5.8	6
34	PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs. Journal of Controlled Release, 2022, 345, 62-74.	9.9	6
35	Theranostic nanomaterials for image-guided gene therapy. MRS Bulletin, 2014, 39, 44-50.	3.5	4
36	Enhancing Systemic Delivery of Enzymatically Generated RNAi Nanocomplexes for Cancer Therapy. Advanced Therapeutics, 2019, 2, 1900014.	3.2	1